Post-MERINO trial: Any role for piperacillin-tazobactam in treating bloodstream infections caused by extended-spectrum beta-lactamase producing Enterobacteriaceae?

2019 ◽  
Vol 53 (5) ◽  
pp. 557-558 ◽  
Author(s):  
Maroun M. Sfeir
Keyword(s):  
Bloodstream Infections ◽  
Beta Lactamase ◽  
Extended Spectrum Beta Lactamase ◽  
Extended Spectrum

scholarly journals Prevalence of Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae Causing Bloodstream Infections in Cancer Patients from Southwest of Iran

2020 ◽  
Vol Volume 13 ◽  
pp. 1319-1326 ◽  
Author(s):  
Effat Abbasi Montazeri ◽  
Azar Dokht Khosravi ◽  
Morteza Saki ◽  
Mehrandokht Sirous ◽  
Bijan Keikhaei ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Bloodstream Infections ◽  
Beta Lactamase ◽  
Extended Spectrum Beta Lactamase ◽  
Extended Spectrum ◽  
Southwest Of Iran

scholarly journals Extended spectrum beta-lactamase producing Enterobacteriaceae causing bloodstream infections in rural Ghana, 2007–2012

2016 ◽  
Vol 306 (4) ◽  
pp. 249-254 ◽  
Author(s):  
Daniel Eibach ◽  
Cristina Belmar Campos ◽  
Ralf Krumkamp ◽  
Hassan M. Al-Emran ◽  
Denise Dekker ◽  
...  
Keyword(s):  
Bloodstream Infections ◽  
Beta Lactamase ◽  
Extended Spectrum Beta Lactamase ◽  
Rural Ghana ◽  
Extended Spectrum

Carbapenems Versus Piperacillin-Tazobactam for Bloodstream Infections of Nonurinary Source Caused by Extended-Spectrum Beta-Lactamase–Producing Enterobacteriaceae

2015 ◽  
Vol 36 (8) ◽  
pp. 981-985 ◽  
Author(s):  
Hadas Ofer-Friedman ◽  
Coral Shefler ◽  
Sarit Sharma ◽  
Amit Tirosh ◽  
Ruthy Tal-Jasper ◽  
...  
Keyword(s):  
Escherichia Coli ◽  
Multivariate Analysis ◽  
Urinary Tract ◽  
Odds Ratio ◽  
Adjusted Odds Ratio ◽  
Bloodstream Infections ◽  
Beta Lactamase ◽  
Extended Spectrum Beta Lactamase ◽  
Efficacy Analysis ◽  
Extended Spectrum

A recent, frequently quoted study has suggested that for bloodstream infections (BSIs) due to extended-spectrum β-lactamase–producing Enterobacteriaceae (ESBL) Escherichia coli, treatment with β-lactam/β-lactamase inhibitors (BLBLIs) might be equivalent to treatment with carbapenems. However, the majority of BSIs originate from the urinary tract. A multicenter, multinational efficacy analysis was conducted from 2010 to 2012 to compare outcomes of patients with non-urinary ESBL BSIs who received a carbapenem (69 patients) vs those treated with piperacillin-tazobactam (10 patients). In multivariate analysis, therapy with piperacillin-tazobactam was associated with increased 90-day mortality (adjusted odds ratio, 7.9, P=.03). For ESBL BSIs of a non-urinary origin, carbapenems should be considered a superior treatment to BLBLIs.Infect Control Hosp Epidemiol 2015;36(8):981–985

Sign in / Sign up

Export Citation Format

Share Document